University of Texas Health Science Center at San Antonio Jun 30 2025 In a multi-institutional study published in  Science Direct , researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for recurrence after treatment. This study analyzed utDNA from patients in the SWOG S1605 trial, who were treated with atezolizumab, an immunotherapy drug. Researchers used the UroAmp test to examine urine samples from 89 patients at the

Tag-uri: DNA